Therapeutic Areas
Oncology & Hematology
Advance your Novel Oncology Therapies to Approval and Commercial Success
When the complexities of designing and executing cancer trials in a highly competitive market can mean delays in delivering urgently needed treatments to patients, it pays to have a trusted partner by your side. In the past five years, our experienced teams have helped clients with more than 480 oncology and hematology studies, prepared more than 70 INDs/CTAs, and more than 30 US and European regulatory marketing applications.
Our expertise encompasses traditional cancer treatments, devices/diagnostics, and specialized therapies, including vaccines, gene and cell therapies, and immunotherapies.
Developing an oncology or hematology therapy?
Oncology/Hematology Experience in the Past 5 Years
+0
Clinical Trials & Consulting Projects
+0
Marketing Applications (NDAs, BLAs, MAAs) Prepared
0%
of global operations team members have oncology/hematology experience
Let's Talk.
Contact Veristat Today!
We know there are always unknown challenges when bringing a novel therapeutics to market, so we’ve assembled an extraordinary team of scientific minded experts who have mastered the complexities of therapeutic development enabling sponsors to succeed in extending and saving lives.
Clinical Trial & Regulatory Consulting Expertise for Cancers & Blood Disorders
Our expertise allows us to confidently handle the most complex trials and patient populations with the attention and focus needed to navigate the cancer and hematology landscape.
Whatever your challenges are, Veristat provides creative and strategic approaches to inform your decision-making, mitigate trial risks, prove safety and efficacy, and achieve approval success. Our regulatory and clinical development experts are poised to launch your oncology or hematology trial:
-
Rapidly advance your clinical trial to its next milestone.
-
Reliably achieve regulatory success with regulatory consulting advice, marketing application support, and regulatory publishing.
-
Gain trusted strategic advice from scientific experts across all disciplines along the clinical development and commercialization pathway.
-
Ensure ongoing safety for marked products with Post-Market Pharmacovigilance.
Scientific Excellence Across Cancer & Hematology Indications
Solid Tumors
- Brain
- Breast
- Gastrointestinal
- Lung
- Skin
- and more...
Rare Cancers
- Acute Myeloid Leukemia
- Glioblastoma
- Hodgkin’s Lymphoma
- Multiple Myeloma
- Pancreatic
- and more...
Blood Diseases
- Beta-Thalassemia
Hemophilia
Sickle Cell Anemia
Thrombocytopenia - Wiskott-Aldrich Syndrome
and more...
Case Study: Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial
A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer. Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges, including slow recruitment, data cleansing post-MSU, and site staffing.
"By partnering with a like-minded, scientifically focused company such as Veristat, we have found a core team of high caliber collaborators who can help us to accelerate the development of our new class of targeted cancer therapies."
Chief Medical Officer
Mid-size Biotech
Learn More with These Resources
Case Study
Advancing Oncology Innovation
Case Study
Dose Escalation with Bayesian Strategies
Case Study
Indication Selection using Adaptive Design